MedTrace Logo

Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor Responders

NCT04487925 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2024-05-09

No results posted yet for this study

Summary

This is a prospective, randomized, single center, phase 4 controlled trial. The study will compare the efficacy of two different strategies for the management of predicted poor response patients under stimulation for IVF/ICSI: up to three MNC cycles (group 1) versus a single GnRH antagonist CFA (group 2).

Conditions

  • Ovarian Reserve
  • Poor Responders
  • IVF

Interventions

DRUG

A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation

CFA will be administered in combination with Follitropin beta.

DRUG

Up to three modified natural cycles with Follitropin beta.

Follitropin beta in a low dose will be given.

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Dominic Stoop, MD, PhD · University Hospital, Ghent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-25
Primary Completion
2024-09-30
Completion
2024-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04487925 on ClinicalTrials.gov